We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 3 of 36 for:    marijuana or cannabis and smoked | United States

Analgesic Efficacy of Smoked Cannabis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00241579
Recruitment Status : Completed
First Posted : October 19, 2005
Last Update Posted : June 23, 2006
Information provided by:
Center for Medicinal Cannabis Research

Brief Summary:
The purpose of this study is to determine whether or not inhaled marijuana displays any pain-relieving properties on experimentally-induced pain.

Condition or disease Intervention/treatment Phase
Pain Hyperalgesia Drug: Smoked Cannabis Phase 1 Phase 2

Detailed Description:

It is important to evaluate the effects of the cannabinoids on facilitated pain as conditions of hyperalgesia more closely approximates the clinical situation. There are limited clinical studies on the effect of the cannabinoids on facilitated pain states. Noyes et al evaluated the analgesic effects of Delta-9-THC in 34 cancer patients with pain. They concluded that 20mg of oral Delta-9-THC was similar to 120mg of codeine (Noyes et al, 1975). Jain et al concluded that 1.5-3mg of intramuscular Levonantradol resulted in significant pain relief as compared to placebo in 56 patients with acute postoperative pain (Jain et al, 1981).

Comparison(s): Three different doses of smoked cannabis will be compared to placebo for the reduction of experimentally induced pain.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Analgesic Efficacy of Smoked Cannabis
Study Start Date : February 2002
Estimated Study Completion Date : January 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
U.S. FDA Resources

Primary Outcome Measures :
  1. Score on a Visual Analog Scale (VAS) of pain severity
  2. McGill Pain Questionnaire (MPQ) Short Form
  3. Neurosensory testing of: 1) warm and cold sensation, 2) warm and cold pain, 3) touch, and 4) mechanical pain. Testing administered using a Thermal Sensory Analyzer, von Frey hair filaments, and a pinch algometer, respectively.

Secondary Outcome Measures :
  1. Trail Making Test (TMT) as a measure of psychomotor speed.
  2. Paced Auditory Serial Attention Test (PASAT) as a measure of speed of information processing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-90
  • Male or Female
  • Subject smoked cannabis within the last six months

Exclusion Criteria:

  • Active opportunistic infections or opportunistic malignancies requiring acute treatment
  • Active substance abuse (alcohol or injection drug)
  • Pulmonary complications (e.g., tuberculosis, asthma)
  • Current use of cannabis (e.g., within 30 days of randomization)
  • Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test before any cannabis or placebo consumption condition
  • Personal or familial history of psychiatric disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241579

United States, California
UC San Diego Medical Center
San Diego, California, United States, 92093
Sponsors and Collaborators
Center for Medicinal Cannabis Research
Principal Investigator: Mark Wallace, M.D. University of California, San Diego

Additional Information:
ClinicalTrials.gov Identifier: NCT00241579     History of Changes
Other Study ID Numbers: C00-SD-107
First Posted: October 19, 2005    Key Record Dates
Last Update Posted: June 23, 2006
Last Verified: June 2006

Keywords provided by Center for Medicinal Cannabis Research:

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs